{"nctId":"NCT00837967","briefTitle":"Study to Investigate the Safety and Efficacy of High Dose of SymbicortÂ® SMART in Japanese Patients","startDateStruct":{"date":"2009-01"},"conditions":["Asthma"],"count":25,"armGroups":[{"label":"First Symbicort, then Terbutaline","type":"EXPERIMENTAL","interventionNames":["Drug: Symbicort Turbuhaler","Drug: Terbutaline Turbuhaler"]},{"label":"First Turbuhaler, then Symbicort","type":"EXPERIMENTAL","interventionNames":["Drug: Symbicort Turbuhaler","Drug: Terbutaline Turbuhaler"]}],"interventions":[{"name":"Symbicort Turbuhaler","otherNames":[]},{"name":"Terbutaline Turbuhaler","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provision of informed consent prior to any study specific procedures\n* A minimum of 6 months documented history of asthma according to the JGL2006/GINA2006 definition\n* FEV1\\> 70% of predicted normal value pre-bronchodilator\n\nExclusion Criteria:\n\n* Having a known or suspected allergy to study therapy (active drugs or additive)\n* Having a known clinical history of hypertension, relevant arrhythmias or other heart disease, eg, ischemic heart disease, cardiomyopathy, valvular heart disease, or heart failure\n* Having been treated with oral, parenteral or rectal glucocorticoids within 4 weeks, or with depot parenteral glucocorticoids within 3 months\n* Respiratory infection significantly affecting the asthma, as judged by the investigator within 4 weeks","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adverse Events","description":"Total number of adverse events","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"PRIMARY","title":"Serum Potassium - Average Concentration From Trapezoidal Area Under the Curve (AUC)","description":"The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.01","spread":"0.25"},{"groupId":"OG001","value":"3.88","spread":"0.26"}]}]}]},{"type":"PRIMARY","title":"Blood Glucose - Average Concentration From Trapezoidal Area Under the Curve (AUC)","description":"The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121.1","spread":"20.3"},{"groupId":"OG001","value":"129.5","spread":"22.0"}]}]}]},{"type":"PRIMARY","title":"Electrocardiogram (ECG)- Average Trapezoidal Area Under the Curve (AUC)","description":"The mean AUC of QTcF (ECG interval measured from the beginning of the Q wave to the end of the T wave, corrected for heart rate using Fridericia's formula)was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"411.71","spread":"15.07"},{"groupId":"OG001","value":"414.33","spread":"14.04"}]}]}]},{"type":"PRIMARY","title":"Vital Sign (Blood Pressure)- Average Trapezoidal Area Under the Curve (AUC)","description":"The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"115.3","spread":"6.3"},{"groupId":"OG001","value":"114.9","spread":"8.0"}]}]}]},{"type":"PRIMARY","title":"Vital Sign (Pulse Rate)- Average Trapezoidal Area Under the Curve (AUC)","description":"The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.0","spread":"6.6"},{"groupId":"OG001","value":"74.1","spread":"7.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":25},"commonTop":["Tremor","Blood Pressure Decreased","Nasopharyngitis","Palpitations","Tachycardia"]}}}